Bella Nisenbaum

Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry

Salomon M. Stemmer, Mariana Steiner, Shulamith Rizel et al. · npj Breast Cancer · 2017 · 87 citations · Full text

Medicine, Oncology, Breast Oncology +14

Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry

Salomon M. Stemmer, Mariana Steiner, Shulamith Rizel et al. · npj Breast Cancer · 2017 · 69 citations · Full text

Medicine, Oncology, Breast Oncology +14

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial

Christoph Zielinski, István Láng, Moshe Inbar et al. · The Lancet Oncology · 2016 · 58 citations

Medicine, Oncology, Pharmacology +12

Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

Ian Smith, Jean‐Yves Pierga, Laura Biganzoli et al. · Breast Cancer Research and Treatment · 2011 · 51 citations

Medicine, Oncology, Breast Oncology +13

Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy

Salomon M. Stemmer, Mariana Steiner, Shulamith Rizel et al. · npj Breast Cancer · 2019 · 30 citations · Full text

Medicine, Oncology, Breast Oncology +16